Repligen Corporation (NASDAQ:RGEN) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Repligen Corporation (NASDAQ:RGEN) has received a consensus rating of "Moderate Buy" from eleven analysts, with an average price target of $169.45.
• Recent changes in analyst ratings include Royal Bank of Canada's increased target price to $204.00 and Wall Street Zen's downgrade to a "hold" rating.
• In the latest quarter, Repligen reported $182.37 million in revenue, exceeding expectations, but fell short on earnings per share, reporting $0.37 against a consensus estimate of $0.40.

Repligen Corporation (NASDAQ:RGEN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are presently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $169.4545.

RGEN has been the topic of a number of recent research reports. Royal Bank Of Canada raised their target price on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a report on Wednesday, July 30th. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a report on Tuesday, April 29th. Stephens raised Repligen to an "overweight" rating and set a $160.00 target price on the stock in a report on Tuesday, July 22nd. Finally, Evercore ISI decreased their target price on Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th.

Insider Buying and Selling

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the firm's stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director directly owned 1,800 shares in the company, valued at $201,834. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Raiffeisen Bank International AG bought a new stake in Repligen during the fourth quarter valued at about $29,000. Twin Tree Management LP bought a new stake in Repligen during the first quarter valued at about $29,000. Hantz Financial Services Inc. raised its holdings in Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 293 shares during the period. Itau Unibanco Holding S.A. bought a new stake in Repligen during the fourth quarter valued at about $40,000. Finally, Signaturefd LLC raised its holdings in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 128 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Stock Performance

RGEN stock opened at $124.79 on Monday. The company has a market cap of $7.02 billion, a P/E ratio of -499.14, a price-to-earnings-growth ratio of 2.30 and a beta of 1.05. Repligen has a 1 year low of $102.96 and a 1 year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The stock's fifty day moving average price is $121.66 and its 200-day moving average price is $131.12.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business's quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter last year, the business earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities analysts forecast that Repligen will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.